Leonard Vernon
Geen lopende functies
Profiel
Leonard Vernon served as Vice President of Finance and Administration at YM BioSciences, Inc. and MTS Allstream, Inc.
Eerdere bekende functies van Leonard Vernon
| Bedrijven | Functie | Einde |
|---|---|---|
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Financieel Directeur/CFO | - |
MTS Allstream, Inc.
 MTS Allstream, Inc. Specialty TelecommunicationsCommunications MTS Allstream, Inc. provides communication and information technology solutions. It provides wire-line voice, high-speed Internet and data, wireless, directory, digital television, security, and alarm monitoring services. The company serves residential and business customers in Manitoba. MTS Allstream was founded in 1983 and is headquartered in Winnipeg, Canada | Financieel Directeur/CFO | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
MTS Allstream, Inc.
MTS Allstream, Inc. Specialty TelecommunicationsCommunications MTS Allstream, Inc. provides communication and information technology solutions. It provides wire-line voice, high-speed Internet and data, wireless, directory, digital television, security, and alarm monitoring services. The company serves residential and business customers in Manitoba. MTS Allstream was founded in 1983 and is headquartered in Winnipeg, Canada | Communications |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
